Explore Video

Dr. Enrique Grande describes case scenario of patient with prostate cancer with high volume
high grade tumor (Gleason 9, 4+5)

View comprehensive coverage of Breast Cancer from ESMO 2022

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

Toripalimab, a PD-1 inhibitor, has emerged as a promising treatment for metastatic or locally advanced recurrent NPC. Toripalimab can significantly improve response rates and prolong survival in patients who have progressed on previous therapies

Anemia is common feature of MDS with 90% patients having anemia at diagnosis or initial presentation. Anemia not only impacts quality of life but is also prognostic in nature.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.

Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.